Martin Huber
2022 - Xilio Therapeutics
In 2022, Martin Huber earned a total compensation of $1.3M as President and Head of R&D at Xilio Therapeutics, a 61% decrease compared to previous year.
Compensation breakdown
Non-Equity Incentive Plan | $242,500 |
---|---|
Option Awards | $607,499 |
Salary | $488,638 |
Other | $8,872 |
Total | $1,347,509 |
Huber received $607.5K in option awards, accounting for 45% of the total pay in 2022.
Huber also received $242.5K in non-equity incentive plan, $488.6K in salary and $8.9K in other compensation.
Rankings
In 2022, Martin Huber's compensation ranked 2,451st out of 5,753 executives tracked by ExecPay. In other words, Huber earned more than 57.4% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 2,451 | 57th |
Manufacturing | 1,347 | 57th |
Chemicals And Allied Products | 607 | 57th |
Drugs | 561 | 58th |
Pharmaceutical Preparations | 403 | 58th |
Huber's colleagues
We found two more compensation records of executives who worked with Martin Huber at Xilio Therapeutics in 2022.
News
Mersana Therapeutics CEO Anna Protopapas' 2023 pay jumps 56% to $4.5M
April 26, 2024
Xilio Therapeutics CEO René Russo's 2023 pay jumps 36% to $3M
April 25, 2024
Xilio Therapeutics CEO René Russo's 2022 pay falls 60% to $2.2M
April 25, 2023
Xilio Therapeutics CEO René Russo's 2021 pay jumps 118% to $5.5M
April 26, 2022